AstraZeneca Initiates Phase 1b/2 Trial of AZD0120 for Relapsed/Refractory Multiple Myeloma
AstraZeneca is conducting Phase 1b/2 trial of AZD0120, a dual CAR T-cell therapy targeting CD19 and BCMA, in patients with relapsed/refractory multiple myeloma.
| Drug | MOA / Company | Stage |
|---|---|---|
| AZD0120 | AstraZeneca | Lead |
Focal Asset
AZD0120
Company
AstraZeneca
Indication
Hematology / CAR T-cell Therapy
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of AstraZeneca's Phase 1b/2 trial for AZD0120 represents a significant advancement in the competitive landscape of CAR T-cell therapies for multiple myeloma. Successful outcomes could enhance AstraZeneca's market position and influence future treatment paradigms in hematologic malignancies.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include trial enrollment rates, interim results, and potential regulatory filings based on trial outcomes.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.